FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978960952> ?p ?o ?g. }

• W1978960952 endingPage "913" @default.
• W1978960952 startingPage "904" @default.
• W1978960952 abstract "Background Fenofibrate was associated with increases in serum creatinine concentrations. The effect of short-term fenofibrate treatment on kidney function was investigated in subjects with normal kidney function. Study Design Double-blind, crossover, placebo-controlled. Setting and Participants 24 middle-aged subjects with normal kidney function (estimated creatinine clearance ≥ 80 mL/min). Intervention Subjects were treated with fenofibrate (160-mg/d tablet) and placebo in two 6-week periods separated by a washout. Outcomes and Measurements The primary outcome measure was glomerular filtration rate measured by means of inulin clearance, with a test of noninferiority to rule out a change in the 95% confidence interval (CI) greater than 20%. Secondary outcomes included effective renal plasma flow measured by means of para-aminohippurate (PAH) clearance, creatinine clearance, creatinine secretion (ratio of creatinine to inulin clearance), serum cystatin C and uric acid, and urinary excretion of creatinine. Glomerular and tubular damage was evaluated by using albumin and retinol-binding protein levels and N-acetyl-β-d-glucosaminidase activity. Results Inulin clearance was unchanged after fenofibrate (change [Δ] between treatments on 6-week values, 0.8 mL/min; 95% CI, −10.5 to 12.2; P = 0.9), but PAH clearance decreased (Δ, −33; 95% CI, −66 to −1; P = 0.05). Changes in inulin and PAH clearances were not greater than 20%. Plasma creatinine level increased (Δ, 0.11 mg/dL; 95% CI, 0.05 to 0.18; P < 0.05), and creatinine clearance decreased (Δ, −9.5 mL/min; 95% CI, −14.4 to −4.7; P < 0.001). Creatinine secretion and urinary creatinine excretion were unchanged (Δ, −0.05; 95% CI, −0.11 to 0.02; P = 0.2; Δ, 0.37 g/24 h; 95% CI, −0.13 to 0.88; P = 0.1, respectively). Plasma cystatin C level increased (Δ, 0.18 mg/L; 95% CI, 0.03 to 0.34; P = 0.02) and serum uric acid level decreased (Δ, −0.7 mg/dL; 95% CI, −1.2 to −0.3; P = 0.1). Urinary albumin and retinol-binding protein levels were unchanged, but urinary N-acetyl-β-d-glucosaminidase activity increased (Δ, 20.0 μmol/h/mmol creatinine; 95% CI, 9.3 to 30.7; P = 0.001). Limitations Short treatment duration and inclusion of healthy subjects precludes conclusions about effects of longer term use in patients with kidney disease. Small changes in glomerular filtration rate may be difficult to detect by using clearance methods. Interference with the creatinine assay cannot be excluded. Conclusion Short-term fenofibrate treatment did not alter glomerular filtration rate by more than 20% in subjects with normal kidney function, but a smaller decrease cannot be ruled out. Increased serum creatinine levels may be caused by decreased creatinine clearance. The explanation for decreased creatinine clearance and increased serum creatinine levels in this study is not clear. Fenofibrate was associated with increases in serum creatinine concentrations. The effect of short-term fenofibrate treatment on kidney function was investigated in subjects with normal kidney function. Double-blind, crossover, placebo-controlled. 24 middle-aged subjects with normal kidney function (estimated creatinine clearance ≥ 80 mL/min). Subjects were treated with fenofibrate (160-mg/d tablet) and placebo in two 6-week periods separated by a washout. The primary outcome measure was glomerular filtration rate measured by means of inulin clearance, with a test of noninferiority to rule out a change in the 95% confidence interval (CI) greater than 20%. Secondary outcomes included effective renal plasma flow measured by means of para-aminohippurate (PAH) clearance, creatinine clearance, creatinine secretion (ratio of creatinine to inulin clearance), serum cystatin C and uric acid, and urinary excretion of creatinine. Glomerular and tubular damage was evaluated by using albumin and retinol-binding protein levels and N-acetyl-β-d-glucosaminidase activity. Inulin clearance was unchanged after fenofibrate (change [Δ] between treatments on 6-week values, 0.8 mL/min; 95% CI, −10.5 to 12.2; P = 0.9), but PAH clearance decreased (Δ, −33; 95% CI, −66 to −1; P = 0.05). Changes in inulin and PAH clearances were not greater than 20%. Plasma creatinine level increased (Δ, 0.11 mg/dL; 95% CI, 0.05 to 0.18; P < 0.05), and creatinine clearance decreased (Δ, −9.5 mL/min; 95% CI, −14.4 to −4.7; P < 0.001). Creatinine secretion and urinary creatinine excretion were unchanged (Δ, −0.05; 95% CI, −0.11 to 0.02; P = 0.2; Δ, 0.37 g/24 h; 95% CI, −0.13 to 0.88; P = 0.1, respectively). Plasma cystatin C level increased (Δ, 0.18 mg/L; 95% CI, 0.03 to 0.34; P = 0.02) and serum uric acid level decreased (Δ, −0.7 mg/dL; 95% CI, −1.2 to −0.3; P = 0.1). Urinary albumin and retinol-binding protein levels were unchanged, but urinary N-acetyl-β-d-glucosaminidase activity increased (Δ, 20.0 μmol/h/mmol creatinine; 95% CI, 9.3 to 30.7; P = 0.001). Short treatment duration and inclusion of healthy subjects precludes conclusions about effects of longer term use in patients with kidney disease. Small changes in glomerular filtration rate may be difficult to detect by using clearance methods. Interference with the creatinine assay cannot be excluded. Short-term fenofibrate treatment did not alter glomerular filtration rate by more than 20% in subjects with normal kidney function, but a smaller decrease cannot be ruled out. Increased serum creatinine levels may be caused by decreased creatinine clearance. The explanation for decreased creatinine clearance and increased serum creatinine levels in this study is not clear." @default.
• W1978960952 created "2016-06-24" @default.
• W1978960952 creator A5007228758 @default.
• W1978960952 creator A5018045411 @default.
• W1978960952 creator A5025066980 @default.
• W1978960952 creator A5029261723 @default.
• W1978960952 creator A5036541833 @default.
• W1978960952 creator A5064557050 @default.
• W1978960952 date "2008-06-01" @default.
• W1978960952 modified "2023-10-18" @default.
• W1978960952 title "Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People" @default.
• W1978960952 cites W1753062699 @default.
• W1978960952 cites W1940569337 @default.
• W1978960952 cites W1971213885 @default.
• W1978960952 cites W1989993094 @default.
• W1978960952 cites W1998811243 @default.
• W1978960952 cites W2000486229 @default.
• W1978960952 cites W2001776350 @default.
• W1978960952 cites W2003602721 @default.
• W1978960952 cites W2013931739 @default.
• W1978960952 cites W2017857355 @default.
• W1978960952 cites W2030094387 @default.
• W1978960952 cites W2032204242 @default.
• W1978960952 cites W2038382302 @default.
• W1978960952 cites W2040558144 @default.
• W1978960952 cites W2059369021 @default.
• W1978960952 cites W2068672773 @default.
• W1978960952 cites W2082627462 @default.
• W1978960952 cites W2084416591 @default.
• W1978960952 cites W2087219735 @default.
• W1978960952 cites W2094160341 @default.
• W1978960952 cites W2099822840 @default.
• W1978960952 cites W2116404316 @default.
• W1978960952 cites W2126803505 @default.
• W1978960952 cites W2129554428 @default.
• W1978960952 cites W2130875981 @default.
• W1978960952 cites W2198678228 @default.
• W1978960952 cites W2313387138 @default.
• W1978960952 cites W2326572183 @default.
• W1978960952 cites W4229962581 @default.
• W1978960952 cites W66119057 @default.
• W1978960952 doi "https://doi.org/10.1053/j.ajkd.2008.01.014" @default.
• W1978960952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18501783" @default.
• W1978960952 hasPublicationYear "2008" @default.
• W1978960952 type Work @default.
• W1978960952 sameAs 1978960952 @default.
• W1978960952 citedByCount "88" @default.
• W1978960952 countsByYear W19789609522012 @default.
• W1978960952 countsByYear W19789609522013 @default.
• W1978960952 countsByYear W19789609522014 @default.
• W1978960952 countsByYear W19789609522015 @default.
• W1978960952 countsByYear W19789609522016 @default.
• W1978960952 countsByYear W19789609522017 @default.
• W1978960952 countsByYear W19789609522018 @default.
• W1978960952 countsByYear W19789609522020 @default.
• W1978960952 countsByYear W19789609522021 @default.
• W1978960952 countsByYear W19789609522022 @default.
• W1978960952 countsByYear W19789609522023 @default.
• W1978960952 crossrefType "journal-article" @default.
• W1978960952 hasAuthorship W1978960952A5007228758 @default.
• W1978960952 hasAuthorship W1978960952A5018045411 @default.
• W1978960952 hasAuthorship W1978960952A5025066980 @default.
• W1978960952 hasAuthorship W1978960952A5029261723 @default.
• W1978960952 hasAuthorship W1978960952A5036541833 @default.
• W1978960952 hasAuthorship W1978960952A5064557050 @default.
• W1978960952 hasConcept C126322002 @default.
• W1978960952 hasConcept C126894567 @default.
• W1978960952 hasConcept C134018914 @default.
• W1978960952 hasConcept C142724271 @default.
• W1978960952 hasConcept C159641895 @default.
• W1978960952 hasConcept C185592680 @default.
• W1978960952 hasConcept C204787440 @default.
• W1978960952 hasConcept C27081682 @default.
• W1978960952 hasConcept C2778110834 @default.
• W1978960952 hasConcept C2779742124 @default.
• W1978960952 hasConcept C2779881121 @default.
• W1978960952 hasConcept C2780091579 @default.
• W1978960952 hasConcept C2780306776 @default.
• W1978960952 hasConcept C55493867 @default.
• W1978960952 hasConcept C71924100 @default.
• W1978960952 hasConcept C87813604 @default.
• W1978960952 hasConceptScore W1978960952C126322002 @default.
• W1978960952 hasConceptScore W1978960952C126894567 @default.
• W1978960952 hasConceptScore W1978960952C134018914 @default.
• W1978960952 hasConceptScore W1978960952C142724271 @default.
• W1978960952 hasConceptScore W1978960952C159641895 @default.
• W1978960952 hasConceptScore W1978960952C185592680 @default.
• W1978960952 hasConceptScore W1978960952C204787440 @default.
• W1978960952 hasConceptScore W1978960952C27081682 @default.
• W1978960952 hasConceptScore W1978960952C2778110834 @default.
• W1978960952 hasConceptScore W1978960952C2779742124 @default.
• W1978960952 hasConceptScore W1978960952C2779881121 @default.
• W1978960952 hasConceptScore W1978960952C2780091579 @default.
• W1978960952 hasConceptScore W1978960952C2780306776 @default.
• W1978960952 hasConceptScore W1978960952C55493867 @default.
• W1978960952 hasConceptScore W1978960952C71924100 @default.
• W1978960952 hasConceptScore W1978960952C87813604 @default.
• W1978960952 hasIssue "6" @default.

• next